Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings ...
Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...
Investors in REGENXBIO Inc. (NASDAQ:RGNX) need to pay close attention to the stock based on moves in the options market lately.
Copyright © 2025 MarketWatch, Inc. All rights reserved.
4d
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc.
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc. CHWY fell sharply in pre-market trading ahead of quarterly earnings ...
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $10.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback